Literature DB >> 22113697

Targeting DNA repair and the cell cycle in glioblastoma.

Brian M Alexander1, Nancy Pinnell, Patrick Y Wen, Alan D'Andrea.   

Abstract

Glioblastoma is a disease with poor outcomes despite standard therapy. Specific targeting of the DNA damage response is a strategy that is becoming increasingly employed in oncology and has intriguing potential for improving outcomes in glioblastoma. DNA damage targeting has implications for improving current therapy as well as the potential to leverage inherent differences in glioblastoma cells to widen the therapeutic window.

Entities:  

Mesh:

Year:  2011        PMID: 22113697     DOI: 10.1007/s11060-011-0765-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  140 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

2.  Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

Authors:  S J Hotte; A Oza; E W Winquist; M Moore; E X Chen; S Brown; G R Pond; J E Dancey; H W Hirte
Journal:  Ann Oncol       Date:  2005-11-10       Impact factor: 32.976

3.  Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation.

Authors:  M Fernet; V Ponette; E Deniaud-Alexandre; J Ménissier-De Murcia; G De Murcia; N Giocanti; F Megnin-Chanet; V Favaudon
Journal:  Int J Radiat Biol       Date:  2000-12       Impact factor: 2.694

Review 4.  Molecular targeting of glioblastoma: Drug discovery and therapies.

Authors:  Ren-Yuan Bai; Verena Staedtke; Gregory J Riggins
Journal:  Trends Mol Med       Date:  2011-03-14       Impact factor: 11.951

Review 5.  Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks.

Authors:  Martin Digweed; Karl Sperling
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation.

Authors:  Gary D Kao; Zibin Jiang; Anne Marie Fernandes; Anjali K Gupta; Amit Maity
Journal:  J Biol Chem       Date:  2007-05-18       Impact factor: 5.157

9.  UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

Authors:  Stephen Welch; Hal W Hirte; Mark S Carey; Sebastian J Hotte; Ming-Sound Tsao; Shirley Brown; Gregory R Pond; Janet E Dancey; Amit M Oza
Journal:  Gynecol Oncol       Date:  2007-05-29       Impact factor: 5.482

10.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

View more
  15 in total

Review 1.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

2.  Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.

Authors:  Qing Ouyang; Gang Chen; Ji Zhou; Lei Li; Zhen Dong; Rui Yang; Lunshan Xu; Hongjuan Cui; Minhui Xu; Liang Yi
Journal:  Neuro Oncol       Date:  2015-07-14       Impact factor: 12.300

3.  Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Authors:  Anand G Patel; Karen S Flatten; Paula A Schneider; Nga T Dai; Jennifer S McDonald; Guy G Poirier; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

4.  Chitooligosaccharides promote radiosensitivity in colon cancer line SW480.

Authors:  Fu-Shi Han; Shi-Jie Yang; Mou-Bin Lin; Ying-Qun Chen; Ping Yang; Jin-Ming Xu
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

5.  The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Authors:  Laura Annovazzi; Valentina Caldera; Marta Mellai; Chiara Riganti; Luigi Battaglia; Daniela Chirio; Antonio Melcarne; Davide Schiffer
Journal:  Int J Oncol       Date:  2015-04-16       Impact factor: 5.650

6.  Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas.

Authors:  H Ma; L Rao; H L Wang; Z W Mao; R H Lei; Z Y Yang; H Qing; Y L Deng
Journal:  Cell Death Dis       Date:  2013-10-31       Impact factor: 8.469

7.  Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition.

Authors:  Cheree Fitzgibbon; Saleh Ihmaid; Jasim Al-Rawi; Terri Meehan-Andrews; Christopher Bradley
Journal:  Invest New Drugs       Date:  2013-09-22       Impact factor: 3.850

8.  O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma.

Authors:  Michael S Bobola; Mohammad Alnoor; John Y-S Chen; Douglas D Kolstoe; Daniel L Silbergeld; Robert C Rostomily; A Blank; Marc C Chamberlain; John R Silber
Journal:  BBA Clin       Date:  2015-06-01

9.  Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.

Authors:  Koji Yoshimoto; Masahiro Mizoguchi; Nobuhiro Hata; Hideki Murata; Ryusuke Hatae; Toshiyuki Amano; Akira Nakamizo; Tomio Sasaki
Journal:  Front Oncol       Date:  2012-12-05       Impact factor: 6.244

10.  Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro.

Authors:  Chao Yang; Deqiang Lei; Weixiang Ouyang; Jinghua Ren; Huiyu Li; Jingqiong Hu; Shiang Huang
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.